Clinical Trial Update: To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BP102 versus Avastin in combination with paclitaxel/carboplatin for first-line treatment of advanced or relapsed non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• BP102
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-small Cell Lung Cancer(NSCLC) | Phase 3 | Status: COMPLETED